Drug Patents owned by Pfizer

1. List of Cibinqo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Daurismo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(8 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives
Jun, 2028

(5 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 21, 2023
Orphan Drug Exclusivity (ODE) Nov 21, 2025

Drugs and Companies using GLASDEGIB MALEATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 21 November, 2018

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Ibrance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(11 days ago)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(11 days ago)

USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
Jan, 2023

(11 days ago)

US11065250 PFIZER Solid dosage forms of palbociclib
May, 2036

(13 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy

Dosage: TABLET;ORAL

How can I launch a generic of IBRANCE before it's patent expiration?
More Information on Dosage

4. List of Lorbrena drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(10 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

US11299500 PFIZER Crystalline form of lorlatinib free base hydrate
Oct, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 2, 2023
Orphan Drug Exclusivity (ODE) Mar 3, 2028
New Indication (I) Mar 3, 2024

Drugs and Companies using LORLATINIB ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Talzenna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420650 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

US8012976 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Oct, 2029

(6 years from now)

US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(8 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 16, 2023

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

NCE-1 date: October, 2022

Market Authorisation Date: 16 October, 2018

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer

Dosage: CAPSULE;ORAL

More Information on Dosage

6. List of Toviaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jan, 2023

(24 days ago)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine
Jun, 2027

(4 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jun 17, 2024
Pediatric Exclusivity (PED) Dec 17, 2024

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TOVIAZ before it's patent expiration?
More Information on Dosage

7. List of Troxyca Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods
Jul, 2025

(2 years from now)

US7815934 PFIZER Sequestering subunit and related compositions and methods
Dec, 2027

(4 years from now)

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 August, 2016

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

8. List of Vizimpro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides
May, 2025

(2 years from now)

US10596162 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

US10603314 PFIZER Method for treating gefitinib resistant cancer
Feb, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 27, 2025
New Chemical Entity Exclusivity (NCE) Sep 27, 2023

Drugs and Companies using DACOMITINIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 27 September, 2018

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation; Administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution

Dosage: TABLET;ORAL

More Information on Dosage

9. List of Xeljanz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 25, 2023

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 25 September, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of XELJANZ before it's patent expiration?
More Information on Dosage

10. List of Xeljanz Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(a month from now)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253523 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US10639309 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 14, 2024

Drugs and Companies using TOFACITINIB CITRATE ingredient

Market Authorisation Date: 23 February, 2016

Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; A method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XELJANZ XR before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in